Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia

Title:Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia

Volume: 17 Issue: 8

Author(s): Alessandro Gozzetti*, Veronica Candi, Corrado Zuanelli Brambilla, Giulia Papini, Alberto Fabbri and Monica Bocchia

Affiliation:

• Department of hematology, Azienda Ospedaliera Universitaria Senese, Policlinico S. Maria alle Scotte, viale Bracci 16, 53100 Siena,Italy

Keywords: CLL, chemotherapy, BTK, BCR, tyrosine, kinase.

Abstract: Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell malignancies. Bruton’s tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms. Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest.

Cite this article as:

Gozzetti Alessandro*, Candi Veronica, Brambilla Zuanelli Corrado, Papini Giulia, Fabbri Alberto and Bocchia Monica, Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (8) . https://dx.doi.org/10.2174/1871520616666160928153342